Cargando…
Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
OBJECTIVE: To evaluate disease activity in patients with relapsing-remitting MS (RRMS) receiving rituximab with an extended dosing interval. METHODS: In the context of COVID-19 pandemic, this was an interim analysis of an ongoing prospective observational study of patients who were stable on rituxim...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357416/ https://www.ncbi.nlm.nih.gov/pubmed/32587103 http://dx.doi.org/10.1212/NXI.0000000000000825 |
_version_ | 1783558681517883392 |
---|---|
author | Maarouf, Adil Rico, Audrey Boutiere, Clemence Perriguey, Marine Demortiere, Sarah Pelletier, Jean Audoin, Bertrand |
author_facet | Maarouf, Adil Rico, Audrey Boutiere, Clemence Perriguey, Marine Demortiere, Sarah Pelletier, Jean Audoin, Bertrand |
author_sort | Maarouf, Adil |
collection | PubMed |
description | OBJECTIVE: To evaluate disease activity in patients with relapsing-remitting MS (RRMS) receiving rituximab with an extended dosing interval. METHODS: In the context of COVID-19 pandemic, this was an interim analysis of an ongoing prospective observational study of patients who were stable on rituximab for at least 6 months and who had a planned extended dosing interval of 24 months. Only data for patients with active RRMS before rituximab were analyzed. RESULTS: Among 177 patients receiving rituximab, 33 had RRMS and MRI activity before rituximab and at least 8 months of follow-up after the last infusion. The mean (SD) age was 40 (14) years, 25 were females, the mean disease duration was 10 (6.8) years, the mean annual relapse rate (ARR) before rituximab was 1.7 (1.3), and the median Expanded Disability Status Scale (EDSS) score before rituximab was 4.5 (1–7). Before extended dosing, when rituximab was infused every 6 months, the mean (SD) ARR decreased to 0.04 (0.1) (p < 0.0001) and the EDSS score to 4 (0–7) (p = 0.04). At the time of this analysis, the median follow-up since the last infusion was 11 (8–31) months. No patient showed relapse or disability progression. In total, 30 patients had at least 1 MRI performed since the last infusion (median time between the last MRI and the last infusion 10 [8–31] months). No MRI showed activity. The CD19(+) cell proportion was >1% for 10 of 25 patients at the last count (median time 8 [6–25] months). CONCLUSIONS: An extended dosing interval for rituximab for patients with stable MS during the COVID-19 pandemic may be associated with a low risk of disease activity. |
format | Online Article Text |
id | pubmed-7357416 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-73574162020-08-03 Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? Maarouf, Adil Rico, Audrey Boutiere, Clemence Perriguey, Marine Demortiere, Sarah Pelletier, Jean Audoin, Bertrand Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: To evaluate disease activity in patients with relapsing-remitting MS (RRMS) receiving rituximab with an extended dosing interval. METHODS: In the context of COVID-19 pandemic, this was an interim analysis of an ongoing prospective observational study of patients who were stable on rituximab for at least 6 months and who had a planned extended dosing interval of 24 months. Only data for patients with active RRMS before rituximab were analyzed. RESULTS: Among 177 patients receiving rituximab, 33 had RRMS and MRI activity before rituximab and at least 8 months of follow-up after the last infusion. The mean (SD) age was 40 (14) years, 25 were females, the mean disease duration was 10 (6.8) years, the mean annual relapse rate (ARR) before rituximab was 1.7 (1.3), and the median Expanded Disability Status Scale (EDSS) score before rituximab was 4.5 (1–7). Before extended dosing, when rituximab was infused every 6 months, the mean (SD) ARR decreased to 0.04 (0.1) (p < 0.0001) and the EDSS score to 4 (0–7) (p = 0.04). At the time of this analysis, the median follow-up since the last infusion was 11 (8–31) months. No patient showed relapse or disability progression. In total, 30 patients had at least 1 MRI performed since the last infusion (median time between the last MRI and the last infusion 10 [8–31] months). No MRI showed activity. The CD19(+) cell proportion was >1% for 10 of 25 patients at the last count (median time 8 [6–25] months). CONCLUSIONS: An extended dosing interval for rituximab for patients with stable MS during the COVID-19 pandemic may be associated with a low risk of disease activity. Lippincott Williams & Wilkins 2020-06-25 /pmc/articles/PMC7357416/ /pubmed/32587103 http://dx.doi.org/10.1212/NXI.0000000000000825 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Maarouf, Adil Rico, Audrey Boutiere, Clemence Perriguey, Marine Demortiere, Sarah Pelletier, Jean Audoin, Bertrand Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? |
title | Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? |
title_full | Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? |
title_fullStr | Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? |
title_full_unstemmed | Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? |
title_short | Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? |
title_sort | extending rituximab dosing intervals in patients with ms during the covid-19 pandemic and beyond? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357416/ https://www.ncbi.nlm.nih.gov/pubmed/32587103 http://dx.doi.org/10.1212/NXI.0000000000000825 |
work_keys_str_mv | AT maaroufadil extendingrituximabdosingintervalsinpatientswithmsduringthecovid19pandemicandbeyond AT ricoaudrey extendingrituximabdosingintervalsinpatientswithmsduringthecovid19pandemicandbeyond AT boutiereclemence extendingrituximabdosingintervalsinpatientswithmsduringthecovid19pandemicandbeyond AT perrigueymarine extendingrituximabdosingintervalsinpatientswithmsduringthecovid19pandemicandbeyond AT demortieresarah extendingrituximabdosingintervalsinpatientswithmsduringthecovid19pandemicandbeyond AT pelletierjean extendingrituximabdosingintervalsinpatientswithmsduringthecovid19pandemicandbeyond AT audoinbertrand extendingrituximabdosingintervalsinpatientswithmsduringthecovid19pandemicandbeyond AT extendingrituximabdosingintervalsinpatientswithmsduringthecovid19pandemicandbeyond |